Meng LY, Yang CT, Bao JF, Huang JS. Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients. World J Gastroenterol 2024; 30(26): 3261-3263 [PMID: 39086637 DOI: 10.3748/wjg.v30.i26.3261]
Corresponding Author of This Article
Jin-Song Huang, Doctor, Chief Doctor, Department of Hepatology, Hangzhou Xixi Hospital, Zhejiang University School of Medicine, No. 2 Hengbu Road, Hangzhou 310023, Zhejiang Province, China. huangjinsongyz@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Li-Yang Meng, Chao-Ting Yang, The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China
Jian-Feng Bao, Jin-Song Huang, Department of Hepatology, Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou 310023, Zhejiang Province, China
Author contributions: Meng LY and Yang CT wrote the manuscript with the support from Huang JS; Bao JF edited this letter; Huang JS conceived the original idea.
Supported byBiomedical Enterprise Project of Hangzhou Science and Technology Bureau, No. 2021WJCY061 and No. 2022WJC230.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jin-Song Huang, Doctor, Chief Doctor, Department of Hepatology, Hangzhou Xixi Hospital, Zhejiang University School of Medicine, No. 2 Hengbu Road, Hangzhou 310023, Zhejiang Province, China. huangjinsongyz@126.com
Received: April 28, 2024 Revised: May 30, 2024 Accepted: June 21, 2024 Published online: July 14, 2024 Processing time: 72 Days and 8 Hours
Abstract
This letter to the editor relates to the study entitled “Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study”, which was recently published by Peng et al. Hepatitis B virus infection represents a significant health burden worldwide and can lead to cirrhosis and even liver cancer. The antiviral drugs currently used to treat patients with chronic hepatitis B infection still have many side effects, so it is crucial to identify safe and effective drugs to inhibit viral replication.
Core Tip: It is well known that every chronic hepatitis B (CHB) patient should receive antiviral therapy. Although nucleos(t)ide analogs are still the first choice for CHB treatment, they are associated with many side effects, such as renal damage, osteoporosis, and lipid metabolism disorders. Therefore, as a new antiviral drug in China, tenofovir amibufenamide (TMF) is as effective as tenofovir alafenamide (TAF) in treating CHB and has comparable safety profiles, which suggests that TMF may be a viable alternative to TAF for CHB treatment.
